LAS GRASAS SATURADAS DISMINUYE EN UN 41% EL NÚMERO DE ESPERMATOZOIDES

 25 Enero, 2013
Las grasas perjudican la calidad del esperma

El consumo de grasas saturadas disminuye en un 41 por ciento el número de espermatozoides y en un 38 por ciento el esperma, según ha mostrado un equipo de investigadores daneses de Rigshospitalet, en Copenhague (Dinamarca), liderados por Tina Jensen.

Para realizar este estudio, que ha sido publicado en The American Journal of Clinical Nutrition, los investigadores encuestaron y examinaron a 701 hombres jóvenes daneses de unos 20 años de edad y realizaron chequeos entre los años 2008 y 2010. A todos ellos, se les preguntó también sobre los alimentos que comían en los últimos tres meses, y se les pidió una muestra de semen. Posteriormente, dividieron los resultados en cuatro grupos, dependiendo de si la cantidad de la ingesta de energía consumida provenía de las grasas saturadas, y compararon la cantidad de esperma de los hombres de cada grupo.

De esta forma, los expertos comprobaron que aquellos que consumían menos de 11,2 por ciento de grasas saturadas tenían una concentración media de espermatozoides de 50 millones por mililitro de semen. «No podemos decir que tiene un efecto causal, pero creo que otros estudios han demostrado que la ingesta de grasa saturada ha demostrado una conexión a otros problemas y ahora también para el recuento de esperma», ha señalado Jensen.

Por debajo de lo normal

De hecho, la Organización Mundial de la Salud define como normal que los hombres tengan más de 15 millones de espermatozoides por mililitro de semen y, en este estudio, tanto el 13 por ciento de los hombres que pertenecían al grupo de menor contenido de grasa, como el 18 por ciento de los hombres del grupo de mayor contenido graso, se situaron por debajo de ese nivel.

No obstante, esta investigación no es la primera en la que se relaciona la dieta con la producción y calidad de espermatozoides, ya que en el año 2011 investigadores brasileños descubrieron que comer más granos -trigo, avena o cebada- está asociado a una mejor concentración y movilidad de espermatozoides, y que ingerir fruta aumenta la velocidad y la agilidad del esperma.

Otro trabajo, publicado en 2012 en Human Reproduction, mostró que los hombres con dietas más ricas en grasas tienen menos esperma y de peor calidad, mientras que aquellos que ingieren más alimentos con grasas polinsaturadas omega-3 -presentes en el pescado y el aceite- tienen un esperma de mejor calidad.

Sin embargo, ese estudio y la mayoría de los otros analizaron estas asociaciones en base a hombres que buscan tratamientos de fertilidad y que, por tanto, pueden no ser representativos de todos los hombres.

HIV CAN BE CURED

Jean Marie Andrie (Nobel prize candidate) - News from 5th NESA Inrternational Surgical Conference 

Université Paris-Descartes, Paris, France

In acute viral infections (such as poliomyelitis, smallpox, measles, Hepatitis B and many others), the virus entering the body for the first time proliferates in its target cells; at the same time, it induces neutralizing antibodies that, although they develop too late to prevent the pathology, eventually eradicate the virus and neutralize any further attack by the same virus. Such viral infections are vaccinable with compositions that are generally made of inactivated virus (or chosen parts of it) and of an adjuvant amplifying the antibody production. Such vaccines generate antiviral antibodies that  neutralize and eradicate the virus before it attacks its target cells.

HIV infection is not a vaccinable infection since the antiviral antibodies raised during the primary infection result in a viral control which is only partial and transitory ; the result is a progressive destruction of the immune system that ends eventually in the various fatal manifestations of  HIV.  Faced to the challenge of that apparently non-vaccinable infection, vaccinologists have tried over the last 25 years to develop prototypes incorporating newly identified viral peptides/epitopes (or their DNA sequences) susceptible to play a role in the infectious process. 

So far, however, their efforts were unsuccessful. In the present talk, I will describe the alternative approach I developed over the last 5 years with my colleague Wei Lu. We based our  research on the observation that a very small percentage (<1%) of HIV-infected patients as well as some SIV-infected macaques  (identified as elite controllers or “EC”) have a strong but non-antibody-dependant control of virus replication (despite the virus still latently infects the nucleus of their target CD4+T-cells).

First, we showed that SIV replication of EC manaques was suppresed by a set of T regulatory cells with a CD8 phenotype. We then developed a new type of vaccine thatdoes not induce SIV-specific antibodies but SIV-specific regulatory CD8+T-cells. We showed that vaccinated monkeys were protected for >1 year from several SIV challenges. It remains to know whether such a suppressive T-cells vaccine is transferable in humans to prevent and treat HIV infection.

Found a new pregnancy hormone

Maternal pregnancy hormone HCG - possible marker for susceptibility

A breakthrough discovery in Leipzig: Source for HCG is not only the trophoblast of the embryo, but also the maternal endometrium. Both forms are encoded by different genes and are distinguishable.

This has several practical implications for the treatment of infertility. On the one hand this could be an explanation for the so-called biochemical pregnancies. I.e. volatile HCG - increases with decrease in the zero-field after a few days. This comes because the usual HCG tests measure the different versions of HCG both together. This is therefore probably not an early miscarriage, but a particularly strong HCG-producing endometrium in this cycle, despite there was no implantation. From this we can conclude that the embryo may have been in these cases even the reason for the failure, eg by aneuploidy.

The other important consequence of the discovery of the mother's HCG would be to take with regard to the optimal timing of implantation. If there are correlations between the receptivity of the endometrium and its HCG production we could perhaps be more accurately determining the implantation - window. We already know that this will not put up equally among all women. Only there are no reliable methods for the determination of this time window. Perhaps the endometrial HCG is a key to it. Further research to go.

Because we feel the ongoing research underestimated and for many years completely ignored we have invited  Prof. Alexander to the 5th NESA – Congress.

Mütterliches Schwangerschaftshormon - möglicher Marker für die Empfänglichkeit

Eine bahnbrechende Entdeckung aus Leipzig: Quelle für HCG ist nicht nur der Trophoblast des Embryo, sondern auch das mütterliche Endometrium. Beide Formen werden durch verschiedene Gen-Abschnitte kodiert und sind unterscheidbar.

Daraus ergeben sich mehrere praktische Folgen für die Sterilitätsbehandlung. Einerseits könnte dies eine Erklärung für die sogenannten biochemischen Schwangerschaften sein. D.h. flüchtige HCG - Erhöhungen mit Abfall in den Null-Bereich nach wenigen Tagen. Denn die üblichen HCG-Teste messen beide unterschiedlichen Varianten des HCG zusammen. Es könnte sich hierbei also nicht um einen sehr frühen Abort, sondern um ein besoneders stark HCG-produzierendes Endometrium in diesem Zyklus handeln, ohne dass es zu einer Einnistung gekommen ist. Daraus kann man schlussfolgern, dass möglicherweise der Embryo in diesen Fällen selbst den Grund für den Fehlschlag gegeben hat, z.B. durch Aneuploidien.

Die andere wichtige Konsequenz aus der Entdeckung des mütterlichen HCG wäre zu ziehen hinsichtlich des optimalen Implantationszeitpunkts. Falls es Zusammenhänge gibt zwischen der Empfänglichkeit des Endometriums und seiner HCG-Produktion liesse sich möglicherweise das Imlantationsfenster genauer bestimmen. Bereits heute wissen wir dass dies nicht bei allen Frauen gleichermassen aufgemacht wird. Nur gibt es noch keine verlässlichen Bestimmungsmethoden für dieses Zeitfenster. Vielleicht ist das endometrielle HCG ein Schlüssel dazu. Weitere Forschungen dazu sind unterwegs.

Weil wir diese seit vielen Jahren laufenden Forschungen als völlig unterbewertet und nicht beachtet hieltenn haben wir Herrn Prof. Alexander zum 5. NESA - Kongress nach Palma eingeladen .

GENIPLET in 5th NESA International Surgicial Conference

Palma de Mallorca, 13-15 September,2012 at Gran Hotel Melía Victoria

We are co-founders of the NESA (New European Surgical Academy). This organization was founded in 2004 in Berlin. Founder and driving force is our Member of the Scientific Board, Prof. Michael Stark.

To celebrate the completion of our hospital in Palma (Geniplet Palma Reproductive Clinic) Mallorca was a selected as destination for the 5th Annual congress.

13th to 15th of August  2012 there gathered approximately 220 participants from the whole world, from 26 countries, and 14 invited speakers on the latest advances in the field of robotics, obstetrics, surgical gynecology and reproductive medicine.

The event was  supported by the Geniplet AG. The conference papers will be bublished in Geniplet - blog.

Our presentation did discuss borderline cases of ART. This is the core competence of Geniplet; For every problem to have a solution in one of our activities in different countries.

Since we have to lament a construction delay, the opening of our clinic is not yet possible. We're already preparing another specific event in May 2013 under the title THINK - TANK BALEAR. We will be hence honored to inivite later again for the physical opening of our clinic.

Wir sind Gründungsmitglieder der NESA (New European Surgical Academy). Diese Organisation wurde 2004 in Berlin gegründet. Gründer und treibende Kraft ist unser Mitglied des Scientific Board, Prof. Michael Stark.

Aus Anlass der Fertigstellung unserer Klinik in Palma (Geniplet Palma, Reproductive Clinic) wurde Mallorca als Ort für den 5. Jahres- Kongress ausgewählt.

Vom 13. bis 15. August trafen sich ca 220 Teilnehmer aus der ganzen Welt, aus 26 Ländern,  sowie 14 eingeladene Referenten um die neuesten Entwicklungen auf dem Gebiet der Robotik, der Geburtshilfe, der operativen Gynäkologie und der Reproduktionsmedizin auszutauschen.

Die Veranstaltung wurde von der GENIPLET AG unterstützt. Die Kongressbeiträge werden wir im Geniplet - Blog veröffentlichen.

Unser Vortrag wird Grenzfälle des Kinderwunsches behandeln. Dies ist die Kernkompetenz von Geniplet: Für jedes denkbare Problem eine Lösung in einer der Aktivitäten in verschiedenen Ländern anbieten zu können.

Da wir eine Bauverzögerung zu beklagen haben wird die Eröffnung unserer Klinik nicht zum Zeitpunkt des Kongresses möglich sein. Wir planen deshalb eine weitere spezifische Veranstaltung im Mai 2013 unter dem Titel THINK - TANK BALEAR und werden entsprechend einladen.

Links:

www.geniplet.com
www.uspnesadays.com
Congress Highlights
www.nesacademy.org

Identical twins start to differ in the womb, study shows

Dr Rebecca Hill Progress Educational Trust BioNews, London Despite sharing the same womb, identical twins are born with different alterations to their DNA that can affect the activity of individual genes. These modifications, known as epigenetic markers, are thought to be caused by environmental factors. The process adds chemical tags to the DNA, which alters a gene's activity, but not its sequence. Although previous studies have shown that identical twins do have different sets of epigenetic markers, it was thought that the changes occurred after birth, when the twins experience different environments. However, in this, the first analysis of the epigenetic profiles of newborn human babies, the team from Murdoch Children's Research Institute, Australia show that differences are already apparent straight after birth. 'Twins, like the rest of us, sit in their own amniotic sac and have their own individual experiences', lead researcher Dr Jeffrey Craig told International Business Times. The study, published in Genome Research, suggests that even small differences in womb environment, such as availability of nutrients or the influence of the placenta and umbilical cord, could be responsible. Dr Craig added: 'Sometimes one placenta could be in the best place in the womb, while the other twin might be shunted off to the side somewhere'. The results also showed that twins who shared a placenta were even more likely to be epigenetically different, potentially because the twins would have had to share the same source of nutrition, and so one would potentially get more than the other. The study, which analysed the umbilical cords, cord blood and placentas from 22 identical and 12 non-identical pairs of twins, showed that the epigenetic profiles of identical twins were more similar than those of non-identical twins. Additionally, differences in birth weight between the twins corresponded to differences in epigenetic markers on genes known to be associated with metabolism, growth and heart disease. Dr Karen Lillycrop, an epigeneticist at the University of Southampton, told Science News that current evidence suggests that 'in terms of metabolism these epigenetic changes can have very long-term effects'. Co-author Dr Richard Saffery hopes the work will add to our understanding of how epigenetic changes influence future health: 'This has potential to identify and track disease risk early in life, or even to modify risk through specific environmental or dietary interventions'.